Update shared on08 Aug 2025
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50.
What's in the News
- Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.
- The company was added to multiple Russell indexes, including 2000, 2500, 3000, Microcap, and various Growth benchmarks.
- Claritev entered a collaboration with Fractional AI to advance its generative AI strategy for healthcare.
- Joined the Coalition for Health AI, aiming to contribute to best practices for responsible AI in healthcare.
- Formalized a strategic partnership with Claims Care Revenue Cycle Management LLC to expand advanced analytics and AI-driven solutions in the MENA region.
Valuation Changes
Summary of Valuation Changes for Claritev
- The Consensus Analyst Price Target remained effectively unchanged, at $49.50.
- The Future P/E for Claritev has significantly risen from 10.12x to 13.52x.
- The Net Profit Margin for Claritev has significantly fallen from 11.52% to 8.63%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.